Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans

Belinda X. Ong, Youngki Yoo, Myeong Gil Han, Jun Bae Park, Myung Kyung Choi, Yeseul Choi, Jeon Soo Shin, Yong Sun Bahn, Hyun Soo Cho

Research output: Contribution to journalArticle

Abstract

CK2α is a constitutively active and highly conserved serine/threonine protein kinase that is involved in the regulation of key cellular metabolic pathways and associated with a variety of tumours and cancers. The most well-known CK2α inhibitor is the human clinical trial candidate CX-4945, which has recently shown to exhibit not only anti-cancer, but also anti-fungal properties. This prompted us to work on the CK2α orthologue, Cka1, from the pathogenic fungus Cryptococcus neoformans, which causes life-threatening systemic cryptococcosis and meningoencephalitis mainly in immunocompromised individuals. At present, treatment of cryptococcosis remains a challenge due to limited anti-cryptococcal therapeutic strategies. Hence, expanding therapeutic options for the treatment of the disease is highly clinically relevant. Herein, we report the structures of Cka1-AMPPNP-Mg2+ (2.40 Å) and Cka1-CX-4945 (2.09 Å). Structural comparisons of Cka1-AMPPNP-Mg2+ with other orthologues revealed the dynamic architecture of the N-lobe across species. This may explain for the difference in binding affinities and deviations in protein-inhibitor interactions between Cka1-CX-4945 and human CK2α-CX-4945. Supporting it, in vitro kinase assay demonstrated that CX-4945 inhibited human CK2α much more efficiently than Cka1. Our results provide structural insights into the design of more selective inhibitors against Cka1.

Original languageEnglish
Article number14398
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Casein Kinases
Cryptococcus neoformans
Virulence
Adenylyl Imidodiphosphate
Cryptococcosis
Neoplasms
Meningoencephalitis
Protein-Serine-Threonine Kinases
Metabolic Networks and Pathways
Fungi
Phosphotransferases
5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid
Clinical Trials
Therapeutics
Proteins

All Science Journal Classification (ASJC) codes

  • General

Cite this

Ong, Belinda X. ; Yoo, Youngki ; Han, Myeong Gil ; Park, Jun Bae ; Choi, Myung Kyung ; Choi, Yeseul ; Shin, Jeon Soo ; Bahn, Yong Sun ; Cho, Hyun Soo. / Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{621b5709843d415fb6b56fcd65ec9f28,
title = "Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans",
abstract = "CK2α is a constitutively active and highly conserved serine/threonine protein kinase that is involved in the regulation of key cellular metabolic pathways and associated with a variety of tumours and cancers. The most well-known CK2α inhibitor is the human clinical trial candidate CX-4945, which has recently shown to exhibit not only anti-cancer, but also anti-fungal properties. This prompted us to work on the CK2α orthologue, Cka1, from the pathogenic fungus Cryptococcus neoformans, which causes life-threatening systemic cryptococcosis and meningoencephalitis mainly in immunocompromised individuals. At present, treatment of cryptococcosis remains a challenge due to limited anti-cryptococcal therapeutic strategies. Hence, expanding therapeutic options for the treatment of the disease is highly clinically relevant. Herein, we report the structures of Cka1-AMPPNP-Mg2+ (2.40 {\AA}) and Cka1-CX-4945 (2.09 {\AA}). Structural comparisons of Cka1-AMPPNP-Mg2+ with other orthologues revealed the dynamic architecture of the N-lobe across species. This may explain for the difference in binding affinities and deviations in protein-inhibitor interactions between Cka1-CX-4945 and human CK2α-CX-4945. Supporting it, in vitro kinase assay demonstrated that CX-4945 inhibited human CK2α much more efficiently than Cka1. Our results provide structural insights into the design of more selective inhibitors against Cka1.",
author = "Ong, {Belinda X.} and Youngki Yoo and Han, {Myeong Gil} and Park, {Jun Bae} and Choi, {Myung Kyung} and Yeseul Choi and Shin, {Jeon Soo} and Bahn, {Yong Sun} and Cho, {Hyun Soo}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-50678-z",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans. / Ong, Belinda X.; Yoo, Youngki; Han, Myeong Gil; Park, Jun Bae; Choi, Myung Kyung; Choi, Yeseul; Shin, Jeon Soo; Bahn, Yong Sun; Cho, Hyun Soo.

In: Scientific reports, Vol. 9, No. 1, 14398, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans

AU - Ong, Belinda X.

AU - Yoo, Youngki

AU - Han, Myeong Gil

AU - Park, Jun Bae

AU - Choi, Myung Kyung

AU - Choi, Yeseul

AU - Shin, Jeon Soo

AU - Bahn, Yong Sun

AU - Cho, Hyun Soo

PY - 2019/12/1

Y1 - 2019/12/1

N2 - CK2α is a constitutively active and highly conserved serine/threonine protein kinase that is involved in the regulation of key cellular metabolic pathways and associated with a variety of tumours and cancers. The most well-known CK2α inhibitor is the human clinical trial candidate CX-4945, which has recently shown to exhibit not only anti-cancer, but also anti-fungal properties. This prompted us to work on the CK2α orthologue, Cka1, from the pathogenic fungus Cryptococcus neoformans, which causes life-threatening systemic cryptococcosis and meningoencephalitis mainly in immunocompromised individuals. At present, treatment of cryptococcosis remains a challenge due to limited anti-cryptococcal therapeutic strategies. Hence, expanding therapeutic options for the treatment of the disease is highly clinically relevant. Herein, we report the structures of Cka1-AMPPNP-Mg2+ (2.40 Å) and Cka1-CX-4945 (2.09 Å). Structural comparisons of Cka1-AMPPNP-Mg2+ with other orthologues revealed the dynamic architecture of the N-lobe across species. This may explain for the difference in binding affinities and deviations in protein-inhibitor interactions between Cka1-CX-4945 and human CK2α-CX-4945. Supporting it, in vitro kinase assay demonstrated that CX-4945 inhibited human CK2α much more efficiently than Cka1. Our results provide structural insights into the design of more selective inhibitors against Cka1.

AB - CK2α is a constitutively active and highly conserved serine/threonine protein kinase that is involved in the regulation of key cellular metabolic pathways and associated with a variety of tumours and cancers. The most well-known CK2α inhibitor is the human clinical trial candidate CX-4945, which has recently shown to exhibit not only anti-cancer, but also anti-fungal properties. This prompted us to work on the CK2α orthologue, Cka1, from the pathogenic fungus Cryptococcus neoformans, which causes life-threatening systemic cryptococcosis and meningoencephalitis mainly in immunocompromised individuals. At present, treatment of cryptococcosis remains a challenge due to limited anti-cryptococcal therapeutic strategies. Hence, expanding therapeutic options for the treatment of the disease is highly clinically relevant. Herein, we report the structures of Cka1-AMPPNP-Mg2+ (2.40 Å) and Cka1-CX-4945 (2.09 Å). Structural comparisons of Cka1-AMPPNP-Mg2+ with other orthologues revealed the dynamic architecture of the N-lobe across species. This may explain for the difference in binding affinities and deviations in protein-inhibitor interactions between Cka1-CX-4945 and human CK2α-CX-4945. Supporting it, in vitro kinase assay demonstrated that CX-4945 inhibited human CK2α much more efficiently than Cka1. Our results provide structural insights into the design of more selective inhibitors against Cka1.

UR - http://www.scopus.com/inward/record.url?scp=85073073249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073073249&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-50678-z

DO - 10.1038/s41598-019-50678-z

M3 - Article

C2 - 31591414

AN - SCOPUS:85073073249

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 14398

ER -